Eganelisib

TargetMol
Product Code: TAR-T5432
Supplier: TargetMol
CodeSizePrice
TAR-T5432-5mg5mg£104.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5432-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5432-10mg10mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5432-25mg25mg£163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5432-50mg50mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5432-100mg100mg£357.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
IPI-549 is an inhibitor of PI3Kγ (IC50 = 16, 3,200, 3,500, and >8,400 nM for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively)
CAS:
1693758-51-8
Formula:
C30H24N8O2
Molecular Weight:
528.576
Pathway:
PI3K/Akt/mTOR signaling
Purity:
0.9956
SMILES:
C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1
Target:
PI3K

References

De Vera AA1, Gupta P.et al.Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.Cancer Lett. 2019 Feb 1;442:91-103 Evans CA, et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-? Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett. 2016 Jul 22;7(9):862-7. Jiang Y, Xiong W, Jia L, et al. Developing a Na?ve Bayesian Classification Model with PI3K? structural features for virtual screening against PI3K?: Combining molecular docking and pharmacophore based on multiple PI3K? conformations. European Journal of Medicinal Chemistry. 2022: 114824. Xiong W, Jia L, Liang J, et al. Investigation into the anti-airway inflammatory role of the PI3K? inhibitor JN-PK1: An in vitro and in vivo study. International Immunopharmacology. 2022, 111: 109102 Xiong W, Jia L, Cai Y, et al.Evaluation of the anti-inflammatory effects of PI3K?/? inhibitors for treating acute lung injury.Immunobiology.2023: 152753. Xiong W, Jia L, Liang J, et al.Investigation into the anti-airway inflammatory role of the PI3K? inhibitor JN-PK1: An in vitro and in vivo study.International Immunopharmacology.2022, 111: 109102.